Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation
Authors:
- Rintaro NoroRNRintaro Noro
- Akihiko GemmaAGAkihiko Gemma
- Seiji KosaihiraSKSeiji Kosaihira
- Yutaka KokuboYKYutaka Kokubo
- Mingwei ChenMCMingwei Chen
- Masahiro SeikeMSMasahiro Seike
- Kiyoko KataokaKKKiyoko Kataoka
- Kuniko MatsudaKMKuniko Matsuda
- Tetsuya OkanoTOTetsuya Okano
- Yuji MinegishiYMYuji Minegishi
- Akinobu YoshimuraAYAkinobu Yoshimura
- Shoji KudohSKShoji Kudoh
Open Access
- 6 December 2006
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 6 (1) , 277
Abstract
Background: Phase III trials evaluating the efficacy of gefitinib (IRESSA) in non-small cell lung cancer (NSCLC) lend support to the need for improved patient selection in terms of gefitinib use. Mutation of the epidermal growth factor receptor (EGFR) gene is reported to be associated with clinical responsiveness to gefitinib. However, gefitinib-sensitive and prolonged stable-disease-defined tumors withoutEGFRgene mutation have also been reported.Methods: To identify other key factors involved in gefitinib sensitivity, we analyzed the protein expression of molecules within the EGFR family, PI3K-Akt and Ras/MEK/Erk pathways and examined the sensitivity to gefitinib using the MTT cell proliferation assay in 23 lung cancer cell lines.Results: We identified one highly sensitive cell line (PC9), eight cell lines displaying intermediate-sensitivity, and 14 resistant cell lines. Only PC9 and PC14 (intermediate-sensitivity) displayed anEGFRgene mutation including amplification. Eight out of the nine cell lines showing sensitivity had Akt phosphorylation without ligand stimulation, while only three out of the 14 resistant lines displayed this characteristic (P= 0.0059). Furthermore, the ratio of phosphor-Akt/total Akt in sensitive cells was higher than that observed in resistant cells (P= 0.0016). Akt phosphorylation was partially inhibited by gefitinib in all sensitive cell lines.Conclusion: These results suggest that Akt phosphorylation without ligand stimulation may play a key signaling role in gefitinib sensitivity, especially intermediate-sensitivity. In addition, expression analyses of the EGFR family,EGFRgene mutation, and FISH (fluorescencein situhybridization) analyses showed that the phosphorylated state of EGFR and Akt might be a useful clinical marker of Akt activation without ligand stimulation, in addition toEGFRgene mutation and amplification, particularly in adenocarcinomas.Keywords
This publication has 23 references indexed in Scilit:
- Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt PhosphorylationClinical Cancer Research, 2006
- Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung CancerJNCI: Journal of the National Cancer Institute, 2005
- Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With GefitinibJournal of Clinical Oncology, 2005
- Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancerLung Cancer, 2005
- Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung CancerJNCI: Journal of the National Cancer Institute, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- ErbB-2 Amplification Inhibits Down-regulation and Induces Constitutive Activation of Both ErbB-2 and Epidermal Growth Factor ReceptorsJournal of Biological Chemistry, 1999
- Molecular analysis of the cyclin-dependent kinase inhibitor genesp15INK4b/MTS21,p16INK4/MTS1,p18 andpl9 in human cancer cell linesInternational Journal of Cancer, 1996
- Epidermal growth factor-related peptides and their receptors in human malignanciesCritical Reviews in Oncology/Hematology, 1995